91É«ÇéƬ

Plenary One: Opioids

Session Chair:ÌýMsÌýCarolyn Paterson

Using linked cohorts to examine population-wide effects of opioid agonist treatments in NSW. |ÌýScientia Professor Louisa Degenhardt, AO

Keynote Address:ÌýThe UK supervised heroin treatment trial: success and failure to advance science, policy and practice. |ÌýProfessor Sir John Strang

Keynote Address:ÌýExamining Trends in Drug-Related Deaths – the crucial importance of cohorts in informing our understanding of changing risks and harms. |ÌýProfessor Matthew Hickman

Global coverage of interventions to prevent and manage injecting drug use related harms in prisons: a systematic review. |ÌýDr Thomas Santo Jr

Development of opioid use disorder following treatment with opioid analgesics for non-cancer pain relief: an Australian state-wide nested case-control study. |ÌýDr Chrianna Bharat

Poster Presentations

SessionÌýChair:ÌýProfessor Mel Miller

Ms Joanna Zhou:ÌýRetention in opioid agonist treatment following childbirth and associated factors.

Ms Kendal Chidwick:ÌýTrends in prescription opioid analgesic utilisation in Australia from 2015 to 2022.

Dr Ria Hopkins:ÌýAge, period, and cohort trends of substance poisoning, alcohol-related disease, and suicide deaths in Australia, 1980-2019..

Ms Olivia Price:ÌýPopulation ageing and the apparent decline in the initiation of injecting drug use in Australia.

Dr Tayla Degan:ÌýCo-occurring DSM-IV mental disorders among people with methamphetamine dependence.

Ms Emily Symes:ÌýPresentations and characteristics of trans and gender-diverse patients presenting to an Australian Emergency Department.

Plenary Two:ÌýNew, Novel, and Trending

Session Chair:ÌýProfessor Nadine Ezard

The Changing Face of Overdose. |ÌýProfessor Shane Darke

Emerging drugs of concern - Prompt Response Network update.|ÌýDr Brendan Clifford

Emerging drug use, harms, and markets trends: Findings from Drug Trends 2024. |ÌýDr Rachel Sutherland

Breakout One:ÌýTreatment & Trials

Session Chair:ÌýProfessorÌýApo Demirkol

New behavioural and pharmacological trials for smoking cessation. |ÌýAssociate Professor Ryan Courtney &ÌýProfessor Hayden McRobbie

LAIB in Prison: A report on qualitative data from patients who commenced treatment during a clinical trial. |ÌýDr Amelia Woods

The impact of the NSW MERIT diversion program reoffending, imprisonment, and health. |ÌýProfessor Donald Weatherburn

We need to talk about contingency management. |ÌýAssociate Professor Rebecca McKetin

Breakout Two:ÌýCommunity Engagement & Responses

Session Chair: Ms Lisa Russell

Defining approaches and research evidence around Community Action to reduce AOD harms | Dr Peter Gates

Due to a camera failure in 'Breakout Two: Community Engagement & Responses', not all recordings have been captured. These presentations are being rerecorded and will be available shortly.

Breakout Three:ÌýStrong Foundations: Pregnancy & Families

Session Chair:ÌýDr Hester Wilson

Influences of methamphetamine use on family relationships: Interviews with family members. |ÌýMs Paige Webb

Effectiveness of prescription smoking cessation pharmacotherapies during pregnancy: a multi-national study. |ÌýDr Alys Havard

Trends in the use of opioid agonist treatment for opioid dependence in pregnancy. |ÌýDr Duong Tran

Use of opioid agonist therapy in pregnancy: Timing of initiation and treatment retention. |ÌýMs Bianca Varney

Plenary Three:ÌýAlcohol

Session Chair:ÌýMrÌýMatthew Craig

WHO's Global Alcohol Action Plan 2022–2030.Ìý What are the critical issues for Prevention and Policy? |ÌýProfessor Jürgen Rehm

Recent trends in alcohol use and harms in Australia. |ÌýDr Wing See Yuen

Alcohol Retailers Lobbying activities: A Comparative Analysis of profit and Non-profit alcohol retail industry body policy submissions. |ÌýDr Michala Kowalski